Aug 20th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Immutep Limited has announced the successful dosing of the initial participant in the first-in-human Phase I trial of IMP761.

Sionna Therapeutics announced that the first participants have been dosed in two Phase 1 trials of SION-719 and SION-451 in healthy volunteers.

Aegle Therapeutics Corp. reveals the initial patient treated in the Phase 1/2a study of AGLE-102™ for Dystrophic Epidermolysis Bullosa.

The U.S. FDA has granted accelerated approval to Gilead's Livdelzi (Seladelpar) for treating primary biliary cholangitis.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) disclosed preclinical data and outlined its strategy to move two advanced RNAi-based candidates, ARO-INHBE and ARO-ALK7.

Incyte and Syndax Pharmaceuticals announced that Niktimvo™ (axatilimab-csfr), an anti-CSF-1R antibody, has been approved by the U.S. Food and Drug Administration (FDA).

TransCode Therapeutics has reported the start of its multicenter, open-label, Phase 1 clinical trial for its primary therapeutic candidate, TTX-MC138.

Alvotech declared that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT06, Alvotech’s planned biosimilar to Eylea® (aflibercept).

CV6 Therapeutics has reported the successful administration of the second patient in its Phase 1a clinical trial assessing CV6-168 in combination with infusional 5-fluorouracil (5-FU) for cancer treatment.

Aug 15th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

UroGen Submits NDA for UGN-102, Aiming for FDA Approval as the First Treatment for Intermediate-Risk, Low-Grade Non-Muscle Invasive Bladder Cancer.